Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
01 juil. 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with...
Codexis to Participate in Jefferies Global Healthcare Conference
22 mai 2024 16h25 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare...
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
20 mai 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled,...
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
14 mai 2024 06h00 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an...
Codexis Reports First Quarter 2024 Financial Results
02 mai 2024 16h05 HE
|
Codexis, Inc.
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer ...
Codexis to Report First Quarter 2024 Financial Results on May 2
18 avr. 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first...
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
11 avr. 2024 07h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s...
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28 févr. 2024 16h05 HE
|
Codexis, Inc.
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected...
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
26 févr. 2024 16h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an...
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
26 févr. 2024 08h05 HE
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health...